SXTP (60 Degrees Pharmaceuticals) EBIT: $-7.57 Mil (TTM As of Mar. 2026)


SXTP 60 Degrees Pharmaceuticals Inc SXTP
44 GF Score
Price $1.69
GF Value $2.07
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is 60 Degrees Pharmaceuticals EBIT?

60 Degrees Pharmaceuticals SXTP +0.90% 44 EBIT is $-7.57 Mil as of Mar. 2026. GuruFocus rates SXTP with a GF Score™ of 44/100 and a GF Value™ of $2.07 (Modestly Undervalued). The stock has 5 warning signs investors should review.

60 Degrees Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was $-2.09 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was $-7.57 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. 60 Degrees Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 was -386.71%. 60 Degrees Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -537.02%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. 60 Degrees Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -70.19%.

60 Degrees Pharmaceuticals  (NAS:SXTP) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

60 Degrees Pharmaceuticals's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=-8.38 * ( 1 - 0% )/( (2.397 + 1.937)/ 2 )
=-8.38/2.167
=-386.71 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5.366 - 1.459 - ( 1.51 - max(0, 1.843 - 4.895+1.51))
=2.397

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=6.763 - 1.488 - ( 3.338 - max(0, 1.876 - 6.26+3.338))
=1.937

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

60 Degrees Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-8.356/( ( (0.246 + max(1.551, 0)) + (0.26 + max(1.055, 0)) )/ 2 )
=-8.356/( ( 1.797 + 1.315 )/ 2 )
=-8.356/1.556
=-537.02 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.51 + 0.657 + 2.218) - (1.459 + 0 + 0.375)
=1.551

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.336 + 0.911 + 1.675) - (1.488 + 0 + 0.379)
=1.055

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

60 Degrees Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=-7.574/10.790
=-70.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

60 Degrees Pharmaceuticals EBIT Related Terms

60 Degrees Pharmaceuticals EBIT Historical Data

* Premium members only.

The historical data trend for 60 Degrees Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

60 Degrees Pharmaceuticals EBIT Chart

60 Degrees Pharmaceuticals Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial -1.09 -2.19 -1.53 -7.95 -7.36

60 Degrees Pharmaceuticals Quarterly Data
Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.88 -1.73 -2.32 -1.44 -2.09

SXTP vs LSBCF, ACUT, PPCB: EBIT Comparison

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's EV-to-EBIT falls into.


SXTP
44GF Score
60 Degrees Pharmaceuticals Inc SXTP
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

60 Degrees Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-7.57 Mil mean?
60 Degrees Pharmaceuticals (SXTP) has a EBIT of $-7.57 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on 60 Degrees Pharmaceuticals.
Is 60 Degrees Pharmaceuticals' EBIT too high?
60 Degrees Pharmaceuticals' current EBIT is $-7.57 Mil. Overall, 60 Degrees Pharmaceuticals has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 60 Degrees Pharmaceuticals' EBIT compare to LSBCF and ACUT?
60 Degrees Pharmaceuticals' EBIT of $-7.57 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals's current EBIT is $-7.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 60 Degrees Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals (SXTP) is currently considered Modestly Undervalued. The stock's GF Value™ is $2.07, compared to a current price of $1.69 — trading 18.4% below its estimated fair value. The current EBIT is $-7.57 Mil. 60 Degrees Pharmaceuticals' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For 60 Degrees Pharmaceuticals (SXTP), the current EBIT is $-7.57 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is 60 Degrees Pharmaceuticals (SXTP) Overvalued in 2026?

Based on GuruFocus' analysis, 60 Degrees Pharmaceuticals stock appears to be undervalued. The current stock price of $1.69 is trading 18.4% below its estimated GF Value™ of $2.07. GuruFocus considers 60 Degrees Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for SXTP:

  • EBIT: $-7.57 Mil
  • GF Value™: $2.07 vs. price of $1.69 (18.4% below fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the SXTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

60 Degrees Pharmaceuticals Business Description

Address 1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
44GF Score

Get the complete analysis for SXTP

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.69
Price
$2.07
GF Value